**Supplemental Table 1.** **Contributing phase II/III studies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study name (protocol number / ClinicalTrials.gov identifier)** | **Number of study sites** | **Participant population / HCV genotype** | **People aged ≤35 years** | **People aged >35 years** |
| C-CORAL1,2 (PN067 / NCT02251990) | 49 | Asia-Pacific countries; TN /GT1 or GT4 | 83 (29.4) | 352 (16.0) |
| Japan phase 2/3 study3 (PN058 / NCT02203149) | 50 | Japanese participants; cirrhotic and noncirrhotic; TN/TE / GT1 | 8 (2.8) | 358 (16.3) |
| C-EDGE Treatment-Naive4 (PN060 / NCT02105467) | 60 | TN / GT1 or GT4 | 40 (14.2) | 366 (16.7) |
| C-EDGE Head-2-Head5 (PN077 / NCT02358044) | 33 | TN/TE / GT1 or GT4 | 25 (8.9) | 104 (4.7) |
| C-EDGE CO-STAR6 (PN062 / NCT02105688) | 55 | TN on opioid agonist therapy / GT1 or GT4 | 42 (14.9) | 245 (11.2) |
| C-SURFER7 (PN052 / NCT02092350) | 68 | CKD; TN; cirrhotic and noncirrhotic / GT1 | 5 (1.8) | 219 (10.0) |
| C-WORTHY8,9 (PN035 / NCT01717326) | 76 | Cirrhotic and noncirrhotic; TN/TE / GT1 | 14 (5.0) | 121 (5.5) |
| C-EDGE Treatment-Experienced10 (PN068 / NCT02105701) | 65 | TE / GT1 or GT4 | 6 (2.1) | 99 (4.5) |
| C-EDGE CO-INFECTION11 (PN061 / NCT02105662) | 37 | HCV/HIV-coinfected; TN / GT1 or GT4 | 23 (8.2) | 193 (8.8) |
| C-EDGE-IBLD12 (PN065 / NCT02252016) | 31 | TN/TE / GT1 or GT4 | 35 (12.4) | 120 (5.5) |
| C-SALT13 (PN059 / NCT02115321) | 9 | Noncirrhotic; TN/TE / GT1 | 0 (0) | 10 (0.5) |
| C-SCAPE14 (PN047/ NCT01932762) | 30 | TN; GT4 | 1 (0.4) | 9 (0.4) |
| Total | — | All participants | 282 (100) | 2196 (100) |

Abbreviations. CKD, chronic kidney disease;GT, genotype; IBLD, inherited blood disorders; TE, treatment-experienced; TN, treatment-naive.

**Supplemental References**

1. George J, Burnevich E, Sheen IS, et al. Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection. Hepat Comm. 2018;2:595–606
2. Wei L, Jia JD, Wang FS, Niu JQ, et al. Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study. J Gastroenterol Hepatol. 2019;34:12–21.
3. Kumada H, Suzuki Y, Karino Y, et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. J Gastroenterol. 2017;52:520–533.
4. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1–13.
5. Sperl J, Horvath G, Halota W, et al. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: a phase III randomized controlled trial. J Hepatol. 2016;65:1112–1119.
6. Dore GJ, Altice F, Litwin AH, et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165:625–634.
7. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–1545.
8. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1087–1097.
9. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1075–1086.
10. Kwo P, Gane E, Peng CY, Pearlman B, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2016. doi: S0016-5085(16)35170-8 [pii];10.1053/j.gastro.2016.09.045 [doi].
11. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319–e327.
12. Hezode C, Colombo M, Bourliere M, et al. Elbasvir/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III study. Hepatology. 2017;66:736–745.
13. Jacobson IM, Poordad F, Firpi-Morell R, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child-Pugh class B cirrhosis (C-salt part A). J Hepatol. 2015;62(suppl 2):S193–S194.
14. Brown A, Hezode C, Zuckerman E, et al. Efficacy and safety of 12 weeks of elbasvir +/- grazoprevir +/- ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study. J Viral Hepat. 2018;25:457–464.